DATA GRAPHICS | Data Byte
Series A funding remained strong in 2022
Despite extended downturn, 2022 was a good year for early venture funding
January 21, 2023 1:19 AM UTC
The financial headaches of 2022 do not appear to have extended to early venture funding of biotechs, according to an analysis of series A rounds in BioCentury’s BCIQ database.
The total amount raised by biotechs in series A rounds fell 8% in 2022 versus 2021, but was still greater than in 2018, 2019 or 2020...